GAITHERSBURG, Md., May 31, 2011 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCBB:CMXI) (the “Company”), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, announces the Company has made a formal submission to the Centers for Medicare & Medicaid Services (“CMS”) requesting reimbursement reconsideration for autologous platelet rich plasma (“PRP”) gel, including the AutoloGel™ System.
